In melanoma, AhR agonists, for example, can activate the AhR-dependent resistant program to induce dedifferentiation, whereas AhR antagonists can abrogate deleterious AhR sustained-activation to overcome dedifferentiation and drug resistance (Corre et al., 2018). This evidence concerns the gene AHR and melanoma.